Currently, much research is ongoing to develop new and effective therapeutic drugs for the treatment of Heart failure. The treatment of HF is dependent on angiotensin-converting enzyme inhibitor, angiotensin receptor II blocker, beta-blockers, and diuretics. Additionally, other therapies, such as aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, diuretics, nitrates, among others are used for the treatment of patients affected by heart failure. Biomarkers provide a low cost, low risk, and quick turnaround method to confirm or exclude a HF diagnosis, help to establish prognosis in the diagnosis, and more fundamentally, may provide substantial information on the complex pathophysiology that defines the syndrome of HF.

LAS VEGAS, April 4, 2023 /PRNewswire/ --DelveInsight's 'Heart Failure Pipeline Insight 2023'report provides comprehensive global coverage of available, marketed, and pipeline heart failure therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the heart failure pipeline domain.

Key Takeaways from the Heart Failure Pipeline Report

Request a sample and discover the recent advances in heart failure drug treatment @ Heart Failure Pipeline Report

The heart failure pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage heart failure drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the heart failure clinical trial landscape.

Heart Failure Overview

Heart failure is a syndrome caused by structural and functional defects in the myocardium that impair ventricular filling or blood ejection. Reduced left ventricular myocardial function is the most common cause of heart failure. Increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate extracellular matrix proliferation, accelerated apoptosis, and genetic mutations are major pathogenic mechanisms leading to heart failure. Heart failure can significantly reduce a patient's functional capacity and increase the risk of death. Diagnosing and treating the disease effectively is critical to avoid recurrent hospitalizations, improve quality of life, and improve patient outcomes.

Heart failure treatment necessitates a multifaceted approach that includes patient education, an optimal medical regimen to improve cardiac contractility, and the prevention/limitation of exacerbations. The primary heart failure symptoms are dyspnea and fatigue, which can limit exercise tolerance and lead to pulmonary and splanchnic congestion and peripheral edema. Heart failure is still a difficult problem and is now regarded as the most difficult challenge in cardiovascular medicine and surgery.

Find out more about drugs for heart failure @ New Heart Failure Drugs

A snapshot of the Heart Failure Pipeline Drugs mentioned in the report:

Drugs

Company

Phase

MoA

RoA

Tirzepatide

Eli Lilly and Company

Phase III

Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists

Subcutaneous

Finerenone (BAY94-8862)

Bayer

Phase III

Mineralocorticoid receptor antagonists

Oral

Firibastat

Quantum Genomics

Phase II

Glutamyl aminopeptidase inhibitors

Oral

HU 6

Rivus Pharmaceuticals

Phase II

Metabolism stimulants

Oral

Elamipretide

Stealth BioTherapeutics

Phase II

Cardiolipin modulators; Free radical scavengers; Mitochondrial permeability transition pore inhibitors

Subcutaneous

TN-301

Tenaya Therapeutics

Phase I

HDAC6 protein inhibitors

Oral

Learn more about the emerging heart failure pipeline therapies @ Heart Failure Clinical Trials

Heart Failure Therapeutics Assessment

Theheart failure pipelinereport proffers an integral view of heart failure emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Heart Failure Pipeline Report

Dive deep into rich insights for new drugs for heart failure treatment; visit@ Heart Failure Medications

Table of Contents

1.

Heart Failure Pipeline Report Introduction

2.

Heart Failure Pipeline Report Executive Summary

3.

Heart Failure Pipeline: Overview

4.

Analytical Perspective In-depth Commercial Assessment

5.

Heart Failure Clinical Trial Therapeutics

6.

Heart Failure Pipeline: Late Stage Products (Pre-registration)

7.

Heart Failure Pipeline: Late Stage Products (Phase III)

8.

Heart Failure Pipeline: Mid Stage Products (Phase II)

9.

Heart Failure Pipeline: Early Stage Products (Phase I)

10.

Heart Failure Pipeline Therapeutics Assessment

11.

Inactive Products in the Heart Failure Pipeline

12.

Company-University Collaborations (Licensing/Partnering) Analysis

13.

Key Companies

14.

Key Products in the Heart Failure Pipeline

15.

Unmet Needs

16.

Market Drivers and Barriers

17.

Future Perspectives and Conclusion

18.

Analyst Views

19.

Appendix

For further information on the heart failurepipeline therapeutics, reach out @ Heart FailureDrug Treatment

Related Reports

Heart Failure Market

Heart Failure Market Insights, Epidemiology, and Market Forecast 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key heart failure companies, including Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, among others.

Heart FailureEpidemiology Forecast

Heart Failure Epidemiology Forecast 2032report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and heart failureepidemiology trends.

Advanced Heart Failure Pipeline

Advanced Heart Failure Pipeline Insight 2023report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the keyadvanced heart failurecompanies, including Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, among others.

Chronic Heart Failure Pipeline

Chronic Heart Failure Pipeline Insight 2023report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the keychronic heart failurecompanies, including Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, among others.

Acute Heart Failure Pipeline

Here is the original post:
Rich Insights into the Heart Failure Clinical Trial Analysis Featuring ... - PR Newswire